Use of Baricitenib to Maintain of Remission

• Status: Recruiting
• Trial end date: 2023-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Baricitinib a selective Janus kinase (JAK) inhibitors 1&2 have been recognized as a potential therapeutic option in systemic lupus (SLE), also known Baricitinib, a JAK inhibitor, has demonstrated efficacy and safety in the treatment of dermatitis and arthritis 1 ; however, no JAK inhibitor studies have been conducted in lupus nephritis (LN) maintain remission to date.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University

Criteria

Inclusion Criteria:

• Clinical diagnosis of Lupus nephritis Disease

• Must be able to swallow tablets

• lupus nephritis in remission

Exclusion Criteria:

• antiphospholipid syndrome disease

• thrombosis history

• sever anemia, leukopenia or thrombocytopenia

• impaired liver and renal function